Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Xenon Pharmaceuticals Inc (XENE)

10.72   0.26 (2.49%) 10-24 14:08
Open: 10.56 Pre. Close: 10.46
High: 10.87 Low: 10.23
Volume: 49,005 Market Cap: 387M
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Burnaby, British Columbia and currently employs 89 full-time employees. The company is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 10.895 - 10.967 10.967 - 11.033
Low: 10.057 - 10.146 10.146 - 10.227
Close: 10.578 - 10.723 10.723 - 10.853

Technical analysis

as of: 2020-10-23 4:50:36 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 13.69     One year: 14.76
Support: Support1: 10.23    Support2: 8.51
Resistance: Resistance1: 11.72    Resistance2: 12.64
Pivot: 11.33
Moving Average: MA(5): 10.64     MA(20): 11.25
MA(100): 11.79     MA(250): 12.52
MACD: MACD(12,26): -0.20     Signal(9): -0.09
Stochastic oscillator: %K(14,3): 11.91     %D(3): 10.17
RSI: RSI(14): 43.54
52-week: High: 18.45  Low: 7.00  Change(%): 20.9
Average Vol(K): 3-Month: 9852  10-Days: 6962

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
XENE has closed above bottom band by 24.4%. Bollinger Bands are 20.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Sat, 24 Oct 2020
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Expected to Announce Quarterly Sales of $10.33 Million - MarketBeat

Fri, 23 Oct 2020
BidaskClub Lowers Xenon Pharmaceuticals (NASDAQ:XENE) to Strong Sell - MarketBeat

Thu, 08 Oct 2020
Xenon Pharmaceuticals Receives FDA Feedback and is on Track to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2-DEE Before Year-End - GlobeNewswire

Thu, 08 Oct 2020
Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy - GlobeNewswire

Mon, 05 Oct 2020
Do Analysts Agree on Xenon Pharmaceuticals Inc (XENE) Stock's Target Price? - InvestorsObserver

Thu, 01 Oct 2020
Should You Review Recent Insider Transactions At Xenon Pharmaceuticals Inc. (NASDAQ:XENE)? - Simply Wall St

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 35
Shares Float (M) 21
% Held by Insiders 6.69
% Held by Institutions 63.63
Shares Short (K) 1,380
Shares Short P. Month (K) 1,210

Stock Financials

EPS -0.890
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 5.190
Profit Margin -102.25
Operating Margin -107.10
Return on Assets (ttm) -11.5
Return on Equity (ttm) -20.5
Qtrly Rev. Growth
Gross Profit (p.s.) -0.915
Sales Per Share 0.780
EBITDA (p.s.) -0.821
Qtrly Earnings Growth
Operating Cash Flow (M) -11
Levered Free Cash Flow (M) -4

Stock Valuations

PE Ratio -12.04
PEG Ratio
Price to Book value 2.07
Price to Sales 13.74
Price to Cash Flow -33.98

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.